Seeking Better Value in Emerging Market Debt

Seeking Better Value in Emerging Market Debt

Our Head of Corporate Credit Research explains why the debt of high-rated EM countries is a viable alternative for investors looking for high yields with longer duration.


----- Transcript -----


Welcome to Thoughts on the Market. I'm Andrew Sheets, head of Corporate Credit Research at Morgan Stanley. Along with my colleagues bringing you a variety of perspectives, today I'll be talking about why – for buyers of investment grade bonds – we see better value in Emerging Markets.

It's Friday May 17th at 2pm in London.

This is a good backdrop for corporate credit. The asset class loves moderation and our forecasts at Morgan Stanley see a US soft landing with growth about 2 percent comfortably above recession, but also not so strong that we think we need further rate increases from the Federal Reserve. Corporate balance sheets are in good shape, especially in the financial sector and the demand for investment grade corporate bonds remains high – thanks to yields, which hover around five and a half percent.

For all these reasons, even though the additional yield that you currently get on corporate bonds, relative to say government bonds is low, we think that spread can remain around current levels, given this unusually favorable backdrop. But we're less confident about longer maturity bonds. Here, credit spreads are much more extreme, near their lowest levels than 20 years. So, what can investors do if they're looking to get some of the advantages of this macro backdrop but still access higher risk premiums.

For investors who are looking for high rated yield with longer duration, we see a better alternative: the debt of high rated countries in the Emerging Markets, or EM. Adjusting for rating, high grade Emerging Market debt currently trades at a discount to corporate bonds. That is for bonds of similar ratings, the spreads on EM debt are generally higher. And this is even more pronounced when we're looking at those longer dated borrowings; the bonds with the maturity over 10 years. In investment grade credit, you get paid relatively little incremental risk premium to lend to a company over 30 years, relative to lending it to 10. But that's not the case in Emerging Market sovereigns. There, these curves are steep. The incremental premium you get for lending at a longer maturity is much higher.

So, what's driving this difference? Well one has been relatively different flows between these different but related asset classes. Corporate bonds have been very popular with investors, enjoying strong inflows year to date. But Emerging Market bond funds have not, and have seen money come out. Relatively weaker flows may help explain why risk premiums in the EM debt market are higher.

Another reason is that the same EM investors who are often seeing outflows have been asked to buy an unusually large amount of EM bonds. Issuance from Emerging Market sovereigns has been unusually high year to date and unusually focused on longer dated debt. We think this may help explain why Emerging Market risk premiums are even higher for longer dated bonds.

The good news? Our EM strategy team thinks some of this issuance surge will moderate in the second half of the year. It's a good backdrop for high rated credit and this week's CPI number, which showed continued moderation. And inflation is further reinforcing the idea that the US can see a soft landing. The challenge is that – that good news has tightened spreads in the corporate market.

While we think those risk premiums can stay low, we currently see better relative value for investors, looking for yield and risk premium in high-rated EM sovereigns – especially for those looking at longer maturities.

Thanks for listening. Subscribe to Thoughts on the Market wherever you get your podcasts and leave us a review. We'd love to hear from you.

Avsnitt(1510)

Special Episode, Part 2: COVID-19 - How Close Are We to a Vaccine?

Special Episode, Part 2: COVID-19 - How Close Are We to a Vaccine?

In the second of a special two-part episode, we talk with biotech equity analyst Matthew Harrison about market response to new data in the race for a vaccine.

24 Juli 20208min

Special Episode: COVID-19 - Preparing for Fall's Second Wave

Special Episode: COVID-19 - Preparing for Fall's Second Wave

In the first of a special two part episode, we talk with biotech equity analyst Matthew Harrison about new case projections ahead of fall and flu season.

23 Juli 20208min

Michael Zezas: States Look to D.C. to Fill Budget Holes

Michael Zezas: States Look to D.C. to Fill Budget Holes

Local and state governments across the U.S. are eagerly watching whether a new round of stimulus will help them address budget shortfalls. Will Congress deliver?

22 Juli 20202min

Mike Wilson: Adapting to The Ninth Wonder of the World

Mike Wilson: Adapting to The Ninth Wonder of the World

Understanding the regime of financial repression we are under, and recent changes in it, is key for successful investment. Chief Investment Officer, Mike Wilson explains.

20 Juli 20204min

Andrew Sheets: Bracing for Challenges Ahead

Andrew Sheets: Bracing for Challenges Ahead

While July contains a number of potentially positive market events, August and September could present a number of potentially problematic ones.

17 Juli 20203min

Michael Zezas: Coronavirus - Why Another Stimulus Deal is Likely

Michael Zezas: Coronavirus - Why Another Stimulus Deal is Likely

Could a new $1 trillion stimulus deal make its way through the halls of Congress before the summer recess? Why the likelihood of a deal is increasing.

15 Juli 20202min

Mike Wilson: U.S. Markets Weigh Optimism; Uncertainty

Mike Wilson: U.S. Markets Weigh Optimism; Uncertainty

U.S. equities—tech stocks in particular—have powered higher since March lows, but investors are still parsing Q2 earnings, a coming election and rising COVID-19 cases.

13 Juli 20204min

Andrew Sheets: Pressure Testing the “Overoptimistic Markets” Argument

Andrew Sheets: Pressure Testing the “Overoptimistic Markets” Argument

The sharp rebound in stock and corporate bond markets has made some question if markets are a bit too upbeat about a speedy recovery. There’s just one problem with this view.

10 Juli 20203min

Populärt inom Business & ekonomi

badfluence
framgangspodden
varvet
rss-jossan-nina
rss-svart-marknad
rss-borsens-finest
uppgang-och-fall
avanzapodden
lastbilspodden
bathina-en-podcast
fill-or-kill
affarsvarlden
borsmorgon
rss-dagen-med-di
rss-kort-lang-analyspodden-fran-di
24fragor
rss-inga-dumma-fragor-om-pengar
kapitalet-en-podd-om-ekonomi
rss-en-rik-historia
tabberaset